Fate Therapeutics starts potentially registrational RECLAIM-LN FT819 trial
Fate Therapeutics (FATE) initiates the potentially registrational RECLAIM-LN clinical trial of FT819 for the treatment of lupus nephritis.
Site Search
Search market news
Find public news by keyword, exact ticker, category and date.
Matching instruments
Open a ticker page for its news coverage. The news search below stays a text search.